Research results determine the future of the company
As part of laboratory studies, PM&HM technologies have been proved to be applicable for the following list of drugs:
No.
Drug
Area of application
Status
1
Hixozide
Tuberculosis
Laboratory tests have been completed. Hexoside and both of its constituent components, Dioxidine and Isoniazid, are compatible with PM&HM technologies.
2
Isoniazid
Tuberculosis
Laboratory tests have been completed. The drug is PM&HM compatible. Marketing authorization condition: change of a packaging.
3
Moxifloxacin
Tuberculosis
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: pre-clinical/clinical trials required (new dosage form, new route of administration)
4
Levofloxacin
Tuberculosis, pneumonia
Laboratory tests in process. Completion period – September 2020.
5
Amikacin
Tuberculosis, pneumonia
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: change of a packaging.
6
Tobramycin
Pneumonia, cystic fibrosis
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: change of a packaging.
7
Gentamicin
Pneumonia
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: change of a packaging.
8
Budesonide
Asthma, COPD
Laboratory tests have been completed. The drug is PM&HM compatible. The world's first budesonide "solution for inhalation" has been developed, suitable for use in MESH nebulizers.
9
Salbutamol
Asthma, COPD
Laboratory tests have been completed. The drug is PM&HM compatible. Marketing authorization condition: change of a packaging.
10
Tiotropium bromide
Asthma, COPD
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: clinical trials (bioequivalence)
11
Ipratropium bromide
Asthma, COPD
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: change of a packaging.
12
Formoterol
Asthma, COPD
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: change of a packaging (import drug translation).
13
Beclometasone
Asthma, COPD
Laboratory tests have been completed.

Refinement required for use with PM&HM technologies.
14
Acetylcysteine
Mucolytics
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: change of a packaging.
15
Ambroxol
Mucolytics
Laboratory tests have been completed. The drug is PM&HM compatible. Marketing authorization condition: change of a packaging.
16
Iloprost
Pulmonary hypertension
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: change of a packaging (import drug translation).
17
Ondansetron
Cancer. Antiemetic drug
Part of the 2020-2021 study plan
18
Metoclopramide
Cancer. Antiemetic drug
Part of the 2020-2021 study plan
19
Pramipexole
Parkinson's disease
Laboratory tests in process. Completion period – September 2020.
20
Levodopa
Parkinson's disease
Laboratory tests in process. Completion period – December 2020.
21
Piribedilum
Parkinson's disease
Part of the 2020-2021 study plan
22
Desloratadine
Antihistamine (allergy)
Laboratory tests have been completed.

The drug is PM&HM compatible.

Marketing authorization condition: pre-clinical/clinical trials required (new dosage form, new route of administration)
23
Cetirizine (Levocetirizine)
Antihistamine (allergy)
Laboratory tests have been completed.

The drug is PM&HM compatible.

Marketing authorization condition: pre-clinical/clinical trials required (new dosage form, new route of administration)
24
Clemastine
Antihistamine (allergy)
Part of the 2020-2021 study plan
25
Dimetindene
Antihistamine (allergy)
Part of the 2020-2021 study plan
26
Doxylamine
Antihistamine (allergy)
Part of the 2020-2021 study plan
27
Enalapril
Heart failure
Laboratory tests in process. Completion period – September 2020.
28
Lisinopril
Heart failure
Laboratory tests in process. Completion period – September 2020.
29
Metoprolol
Heart failure
Part of the 2020-2021 study plan
30
Losartan
Heart failure
Laboratory tests in process. Completion period – September 2020.
31
Ribavirin
Antiviral drug
Part of the 2020-2021 study plan
32
Fluconazole
Antifungal drug
Part of the 2020-2021 study plan
33
Dioxydin
Antibacterial drug
Laboratory tests have been completed. The drug is PM&HM compatible. Marketing authorization condition: change of a packaging.
34
Miramistin
Antibacterial drug
Laboratory tests have been completed. The drug is PM&HM compatible.

Marketing authorization condition: change of a packaging.